John Kennedy, MD
Pulmonary Disease · Boston, MANPI 1811211444
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $575 of the $660 with a category attached, or 87.1%. Eli Lilly accounts for 87.1% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $575 and has fallen 92.5% since, to $43 in 2025.
Across 4 payments — averaging $165.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$575
- Pfizer$43
- Fisher & Paykel Healthcare Inc$22
- Mylan Specialty L.p.$20
Across 4 payments — averaging $99,751 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$399K
What the payments were for
- Consulting fees$57587%
- Food & beverage$8513%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 1 | $575 |
| Pfizer | 1 | $43 |
| Fisher & Paykel Healthcare Inc | 1 | $22 |
| Mylan Specialty L.p. | 1 | $20 |
How this compares
$660 in reported general payments places this provider in the 60th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 29 | $988,586 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $446 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Boston
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Adnan MajidBoston$351K
- Nicholas HillBoston$293K
- Harrison FarberBoston$190K
- Tufik AssadBoston$132K
- Anthony FaugnoBoston$132K
- Hyun KimBoston$117K
- George WashkoBoston$101K
- Aaron WaxmanBoston$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.